The MedTech company aims to dispel the myths behind cellulite, the number one concern for women’s bodies, and to present the real results of Avéli® to help women understand and deal with cellulite long-term
MOUNTAIN VIEW, CA., September 5, 2023 /PRNewswire/ — Revelle Aestheticsa company backed by VC Silicon Valley MedTech, is focused on designing precision technologies that target the root cause of women’s most vexing cosmetic concerns, starting with its first device to treat cellulite; Aveli®. Today, in honor of National Cellulitis Day, the brand debunks the most common myths surrounding the skin condition that affects up to 90% of women1, such as the belief that cellulite is caused by poor diet or insufficient exercise and that there is no real solution for women who are bothered by it. To overcome skepticism and doubt, Revelle Aesthetics collected hundreds of real results from women who turned to its one-time, in-office procedure for help, as shared by medical aesthetics providers on social media.
Although cellulite is extremely common, it is a cosmetic concern that can significantly affect the self-esteem and social activities of those women who are bothered by it and who have tried a myriad of products over the years to get rid of it. In fact, cellulite is so emotional for women that NewBeauty’s Summer 2023 The State of Aesthetics The report revealed that cellulite was the number one body concern that patients wish to eliminate for good. Unfortunately, cellulite is complicated and, historically, quite difficult to treat – until Avéli®.
Cellulitis is any dimple or depression seen on the surface of the skin with a defined edge and is mainly caused by shortened or hardened bands of septa under the skin that pull down the dermis, causing the dimpling effect. It is important to differentiate cellulite from loose skin (sagging) and fat (pockets of fat) because these conditions, while often occurring side by side, are treated quite differently.
Avéli® was developed to help reduce the physical and mental effects cellulite can have on women and ultimately deliver the meaningful results women want. It is the first and only cellulite device that allows a provider to identify and release the main underlying cause of cellulite (diaphragmatic zones) and confirm release in real time. Aveli® can provide permanent cellulite reduction on the buttocks and thighs in just one in-office procedure that takes about an hour with local numbing and little to no downtime.
“There are so many products out there that are marketed as anti-cellulite miracles, but the truth is, if you’re using a topical product, it’s just not going to work,” says Dr. Ashley Amalfiboard certified plastic surgeon and partner at the Quatela Center for Plastic Surgery in Rochester, New York. “To really address the root cause of cellulite, the septal bands must be manually released from the inside. With Avéli®, not only can I accurately release these bands but also confirm in real time that I did so. This gives me confidence that I am delivering the long-term cellulite reduction results my patient is looking for.”
According Global Cellulite Treatment Market Report and Forecast 2023 – 2031the global cellulite treatment market size reached a price of approx $1.75 billion in 2022. Specifically, North America dominates the global cellulite treatment market due to high demand for cosmetic procedures, evidenced by liposuction remaining the top plastic surgery procedure for the second consecutive year, as reported by The Aesthetic Society. As demand shifts to the lower body, it creates a unique need for innovative treatments like Avéli®.
“Revelle Aesthetics and Avéli® Aiming to help women feel confident about their bodies, whether they have cellulite or not, as we truly believe that all women and all body types deserve to be celebrated,” she says. Caroline Van Hove, President & CEO of Revelle Aesthetics. “We just want to provide a long-term solution2 which offers meaningful results for those who are troubled by their cellulite, so that they can have the best relationship with themselves. It is a testament to Avéli’s transformative results® can pay off by seeing so many providers sharing their patients’ results on social media, suggesting to women that there is finally something that can help achieve the results they desire.”
Aveli® continues to support the cellulite conversation on social media with more than 2,500 mentions on Instagram from providers and patients this year. For more information on the minimally invasive in-office cellulite solution2 for women bothered by cellulite, visit MyAveli.com and follow @aveli on Instagram.
###
ABOUT AESTHETIC REVELLE
Revelle Aesthetics is a Silicon Valley-based MedTech company focused on innovating smart solutions that address the root causes of women’s most vexing aesthetic concerns. The company is committed to developing precision technologies that deliver meaningful results for women and reliable results for doctors. Revelle Aesthetics’ first device, Avéli®, is FDA-approved for long-term reduction of the appearance of cellulite on the buttocks and thighs of adult females, as supported by clinical data demonstrating treatment benefits through one year of observation. It was founded in 2018 and is based in Mountain View, CaliforniaRevelle Aesthetics is a privately held company backed by leading venture capital firms New Enterprise Associates and KCK Medtech. For more information visit www.RevelleAesthetics.com.
-
Emanuele E. Cellulitis: advances in treatment: facts and controversies. Clin Dermatol. 2013? 31 (6): 725-30.
-
Stevens WG, et al. Aesthet Surg J. 2023;43(4):455-466.
Media contact:
Nandy Millett
nmillett@lippetaylor.com
View original content for downloading media:https://www.prnewswire.com/news-releases/revelle-aesthetics-brings-cellulite-education-to-the-forefront-in-celebration-of-national-cellulite-day-301916339.html
SOURCE Avéli
